Related Experiment Video

Updated: Nov 30, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.9K

Metformin and proliferation of cancer cell lines

Karolina Tądel1, Benita Wiatrak2, Dorota Bodetko2

  • 1Faculty of Pharmacy, Wroclaw Medical University, Poland.

Pediatric Endocrinology, Diabetes, and Metabolism
|November 16, 2020
PubMed
Abstract

Insights

Metformin demonstrated anti-cancer effects by reducing cancer cell proliferation in laboratory tests. This common diabetes drug shows promise in cancer treatment research.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Metformin is a key drug for type 2 diabetes and insulin resistance.
  • Emerging research explores metformin's potential in cancer prevention and treatment.

Purpose of the Study:

  • To evaluate metformin's impact on cancer cell viability and proliferation under normoglycemic and hyperglycemic conditions.
  • To compare metformin's effects across various human cancer cell lines (MCF-7, MCF-7/DX, A549, CCRF/CEM, THP-1) and normal human dermal fibroblasts (NHDF).

Main Methods:

  • Cancer cell lines were exposed to varying glucose concentrations (40-300 mM) and metformin doses (5-30 mM).
  • Cell viability was assessed using the MTT assay after incubation periods of 24, 48, 72, and 96 hours.
  • The study simulated normoglycemic (approx. 100 mM glucose) and hyperglycemic environments.

Main Results:

  • Metformin significantly reduced the viability of all tested cancer cell lines under normoglycemic conditions.
  • Shorter incubation times (24-48 hours) yielded more favorable results in reducing cancer cell populations compared to longer periods (72-96 hours).
  • Metformin demonstrated a dose-dependent effect on decreasing cancer cell proliferation.

Conclusions:

  • Metformin exhibits a confirmed anti-cancer effect by lowering cancer cell proliferation.
  • The drug shows beneficial effects in reducing the percentage of viable cancer cells.
  • Metformin's potential as an anti-cancer agent warrants further investigation.
Keywords:
cell culturegrowthmetforminproliferationcancer cell lines

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.5K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.0K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
482
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K